HRT and Breast Cancer Risk: The Real Numbers by Type

The HRT Index is the independent menopause-HRT decision resource for women. Some links on this page are affiliate links, which means we may earn a commission if you start care through them — at no extra cost to you. It never changes our guidance: we don’t rank or recommend any provider based on payment, and the medical information here is independent of any commercial relationship.

Here’s the honest answer about HRT and breast cancer risk: it depends almost entirely on which kind of HRT you mean.

Combined HRT — estrogen plus a progestogen — carries the clearest increase, and even that is small: about 8 extra breast cancer cases per 10,000 women each year in the landmark Women’s Health Initiative trial. Estrogen-only HRT, used by women without a uterus, showed little to no increase — and in that same trial, slightly lowerrisk. Vaginal estrogen barely registers. The risk grows the longer you take combined HRT. It usually drops after you stop — though newer data show some extra risk can linger for more than a decade after longer use. And yes, the FDA changed the warning label in February 2026. What that did and didn’t mean is one of the most misread parts of this whole story, and we’ll clear it up below.

So before you scroll, here’s the one-screen version: there is no single number for “HRT and breast cancer.” There are several, and the right one for you depends on the type of HRT, how long you’d take it, whether you still have your uterus, your family history, and whether you’ve ever had breast cancer yourself. This table shows where you likely fit.

Find your situation: HRT and breast cancer risk at a glance

Sources: Women’s Health Initiative (JAMA); Collaborative Group on Hormonal Factors in Breast Cancer (The Lancet, 2019); U.S. National Cancer Institute; U.S. FDA; ACOG. Full links in each section below. These are population averages, not your personal risk — use them to start a smarter conversation, not to replace one.

If you can’t tell which row is yours, that’s normal — and it’s exactly what the rest of this page is for.

Does HRT cause breast cancer?

Some forms of HRT can raise breast cancer risk — but “HRT” is too broad a word to answer safely as one thing. The clearest increase is with full-body (systemic) estrogen plusa progestogen. Estrogen-only therapy and low-dose vaginal estrogen have very different evidence and shouldn’t be lumped in with it. The honest summary: combined HRT raises the risk a little; estrogen-only barely or not at all; vaginal estrogen essentially not at all.

Let’s start by naming the fear, because most pages skip past it. If you’re here, you probably want HRT — maybe you’re not sleeping, the hot flashes are wrecking your days, your mood or your sex life has changed, and a friend or a doctor mentioned hormones could help. Then you read a scary headline, or someone in your life raised an eyebrow, and now you’re stuck. You don’t want to trade hot flashes for cancer. That’s a completely reasonable thing to be afraid of, and you deserve a straight answer instead of either a brush-off or a scare.

Here’s the straight answer: the risk is real for one type of HRT, small in size, and shaped heavily by your own situation. It is not a coin flip, and it is not a death sentence. It’s a number you can understand and a decision you can make with a clinician once you see the parts clearly.

Why the answer online seems to contradict itself

If you’ve searched this before, you’ve probably seen one page say “HRT causes breast cancer” and another say “HRT is safe and we were wrong for 20 years.” Both are oversimplifying. Here’s why they disagree.

Back in 2002, a huge U.S. study called the Women’s Health Initiative (WHI)— a randomized trial, which is the strongest kind of medical study — stopped early because the women taking combined HRT had more breast cancer and more heart problems than the women taking a placebo. The headlines were enormous. HRT use fell off a cliff almost overnight.

But there was a catch that took years to sink in. The average woman in that study was 63 years old— more than a decade past the typical age of menopause — and they used an older hormone formulation that’s less common today (U.S. FDA). Starting HRT at 63 is a different decision than starting it at 51 when your symptoms begin. Later research found that for women who start near menopause — usually before age 60 or within 10 years of their last period— the benefit-to-risk picture looks much friendlier.

So the “HRT is dangerous” camp is mostly quoting the 2002 alarm. The “HRT is safe now” camp is mostly quoting the newer, age-aware reading. The truth lives in the details: which HRT, what age, how long, and who you are.

The three questions that decide your answer

Before any number means anything for you, three things have to be settled:

1. What type of HRT? Combined (estrogen + progestogen), estrogen-only, vaginal/local, or compounded? These carry very different risk signals.
2. Who’s taking it? Do you have a uterus? How old are you? How long since menopause? Any personal or family history of breast cancer?
3. How long and how much? Risk rises with the years you use combined HRT, and lower doses generally carry less.

Answer those three, and the fog usually lifts. The rest of this page walks through each one.

The real numbers: how much does HRT actually raise the risk?

The most useful numbers are absolute ones — real people, not percentages that sound scary on their own. In the WHI trial, combined HRT was linked to about 8 extra invasive breast cancers per 10,000 women each year. Estrogen-only therapy added far fewer cases, and in that trial actually lowered the risk. A vague “increased risk” tells you nothing; these numbers tell you the size.

Here are the main findings side by side — the thing almost no other page gives you in one place.

Sources: WHI/JAMA; Collaborative Group on Hormonal Factors in Breast Cancer, The Lancet 2019; Million Women Study, The Lancet 2003.

Notice the pattern across every one of these: combined HRT shows a small, real increase that grows with time. Estrogen-only shows little, none, or even a decrease. That consistency is why we trust the overall shape of the picture, even when the exact figures differ.

For context, the 2019 analysis put it this way: out of 100 women of average weight who never use HRT, about 6.3 will be diagnosed with breast cancer between ages 50 and 69. Five years of estrogen plus daily progestogen from age 50 nudges that to about 8.3 — the “1 in 50” extra. Ten years of use roughly doubles the extra (The Lancet, 2019).

Relative risk vs. absolute risk (this is where people scare themselves)

When a study says risk “doubled,” that’s relativerisk — a multiplier. It sounds terrifying. But if the thing being doubled is rare, the absolute change can still be tiny. Doubling a 1-in-1,000 chance gets you to 2-in-1,000. Still small.

The flip side is true too: if your baseline risk is already high — say, a strong family history — the same multiplier moves a bigger number, so it matters more for you than for someone at average risk. This is exactly why a single national statistic can’t answer your personal question, and why “talk to your doctor” isn’t a dodge. It’s the only way to plug your baseline into the math.

Why the WHI numbers don’t fit every modern HRT plan

One honest limit: the WHI tested specificproducts — a particular pill combining conjugated equine estrogen and a synthetic progestogen called medroxyprogesterone acetate. The study’s own authors cautioned that you can’t automatically apply those results to lower doses, to patches and gels instead of pills, or to different progestogens without separate evidence. Newer formulations may behave differently — more on that next.

Estrogen-only vs. combined HRT: the one difference that changes everything

The single biggest driver of HRT’s breast cancer risk is whether it contains a progestogen. Estrogen-only therapy (for women without a uterus) shows little or no increase — and lowered risk in the WHI trial. Adding a progestogen, which is required to protect the uterus in women who still have one, is what introduces the small, time-dependent increase.

Here’s the logic in plain terms. If you still have your uterus, you can’t safely take estrogen by itself. Estrogen alone stimulates the lining of the uterus and raises the risk of endometrial cancer (cancer of the uterine lining). So doctors add a progestogen— an umbrella term for progesterone-like medicines that protect that lining. The progestogen solves the uterus problem. But it’s also the ingredient most tied to the small bump in breast cancer risk.

If you’ve had a hysterectomy and no longer have a uterus, you don’t need the progestogen at all. You can take estrogen alone — and that’s the version with the friendliest breast cancer evidence. The U.S. National Cancer Institute lists “lower risk of breast cancer” and “lower risk of death from breast cancer” among the potential effects of systemic estrogen (NCI).

We’ll be straight about one disagreement here: the WHI randomized trial found lower breast cancer risk with estrogen-only, while some large observational studies have reported a small increase. That’s why the honest framing is “reassuring, but not a breast-cancer-prevention strategy” — not “estrogen-only is risk-free.”

And one trade-off in writing: even after the 2026 label changes, the FDA kept the endometrial-cancer warning in place for full-body estrogen-alone products (U.S. FDA). Estrogen alone is gentler on breast risk, but it’s not the right choice for someone with a uterus.

Which type of HRT has the lowest breast cancer risk?

For breast cancer specifically, low-dose vaginal estrogen carries essentially no increase, and estrogen-only systemic therapy carries little to none. Among combined options, estrogen paired with micronized (body-identical) progesterone has not been shown to raise risk in shorter-term use, while older synthetic progestins carry more. Lower doses, shorter durations, and starting before 60 all push the risk down.

Here’s how the routes rank, lowest risk first.

1. Low-dose vaginal estrogen — the lowest

Low-dose vaginal estrogen (creams, rings, or tablets applied directly) is treated separately from full-body HRT because very little enters the bloodstream. The landmark 2019 worldwide analysis found excess breast cancer risk for every systemic HRT type except vaginal estrogen. If your symptoms are dryness, painful sex, or recurring urinary infections, this is the most reassuring route for breast risk. The one caveat: women who have already had breast cancer should still discuss it with their oncology or menopause clinician, especially if they take estrogen-blocking drugs like tamoxifen or aromatase inhibitors. See our vaginal estrogen guide for more on what’s available.

2. Estrogen-only systemic therapy — reassuring, not risk-free

For women without a uterus, estrogen-only HRT (patches, gels, pills, or sprays) is the systemic option with the most reassuring breast cancer evidence. The WHI randomized trial found about a 23% lowerrisk over 11 years with estrogen-alone therapy. Some observational studies have reported a small increase instead — which is why “reassuring” is the right word, not “risk-free.” If you still have your uterus, this route is off the table due to endometrial cancer risk. Uterus status is the first and most decisive question.

3. Estrogen + micronized (body-identical) progesterone — the better combined option

For women who still have a uterus and need a progestogen alongside estrogen, micronized progesterone (such as FDA-approved Prometrium) has a more encouraging short-term evidence base than older synthetic progestins. Large observational data — including the French E3N cohort study — suggested lower breast cancer risk with natural progesterone compared to synthetic progestins over 5–7 years. The evidence is still maturing for very long-term use, and it’s not a guarantee. But if you’re choosing between progestogen types, this is the more reassuring current data point to discuss with your clinician. Note: FDA-approved body-identical estradiol and progesterone already exist, so there is usually no medical reason to use compounded products for this benefit.

4. Estrogen + synthetic progestins — the clearest increased-risk signal

This is what the WHI tested: conjugated equine estrogen plus medroxyprogesterone acetate (MPA), an older synthetic progestogen. This combination produced the most cited breast cancer finding: about 8 extra cases per 10,000 women per year, or roughly 1 extra case per 50 women over 5 years from age 50 (daily dosing). Risk grew with longer use. Other synthetic progestins have somewhat different profiles, but the clearest trial evidence relates to this combination. If you’re offered combined HRT with a synthetic progestogen, it’s worth asking whether micronized progesterone is appropriate for your situation instead.

5. Compounded hormones — no evidence of lower risk

Pharmacy-compounded “bioidentical” hormones are often marketed as safer or more natural. There is no reliable evidence that they are safer for breast cancer. FDA-approved body-identical estradiol and progesterone already exist and are available from most online providers. Compounded products are not FDA-approved, not independently tested for long-term cancer risk, and the FDA and ACOG advise against using them routinely when approved options are available. See our bioidentical vs. compounded HRT guide for a full breakdown.

This table summarizes relative signals, not personal risk. Talk to a clinician about what applies to your specific history. Last verified June 16, 2026.

How long you take HRT changes the answer

Duration is one of the clearest variables in the breast cancer risk picture. The 2019 worldwide pooled analysis put it this way for combined HRT starting from age 50:

• 5 years of estrogen + daily progestogen: about 1 extra case per 50 women over 20 years
• 5 years of estrogen + intermittent progestogen: about 1 extra case per 70 women over 20 years
• 5 years of estrogen-only: about 1 extra case per 200 women over 20 years
• 10 years of combined use: roughly doubles the extra, compared to 5 years

Lower doses appear to carry lower risk, though the trial data don’t yet give precise dose-response curves for every modern product. Shorter is generally safer for breast risk, which is why current guidance points toward using the lowest effective dose for the shortest appropriate time— while acknowledging that longer use is sometimes the right call for ongoing symptoms and bone protection.

Does the risk go away if I stop HRT?

Mostly, yes — but not necessarily quickly. The extra risk from combined HRT generally declines after stopping. Older pooled data suggested it largely wore off after about five years. But the 2019 Collaborative Group analysis and the National Cancer Institute find that some excess risk can persist for more than 10 years, especially after longer use. The longer you took combined HRT, the longer the tail. Stopping is still worth doing if the benefits no longer outweigh the risks — but “stopping erases everything immediately” is not quite right for longer courses.

What the 2026 FDA change actually means

On February 12, 2026, the FDA removed breast cancer, heart disease, and dementia language from the boxed warning(the most prominent “black box” warning) of the first six menopausal hormone products. This generated a wave of headlines saying HRT had been “cleared” or that “the government finally admitted it was safe.” That’s not quite what happened.

Here’s what actually changed and what didn’t:

• What changed:Breast cancer, heart disease, and dementia were moved out of the highest-visibility boxed warning into the label’s Warnings and Precautions section. The agency’s position was that the boxed warning overstated risks for younger menopausal women based on an older study of older women.
• What stayed:Breast cancer risk information is still in the label — just not in the most prominent box. The endometrial-cancer boxed warning remained for systemic estrogen-alone products.
• What the underlying science didn’t change:The WHI and Collaborative Group data didn’t disappear. The change reflects a reinterpretation of how to communicate those risks, not a finding that the risks are zero.

The practical takeaway: the 2026 update means the label better reflects age-appropriate risk for women starting HRT near menopause. It does not mean combined HRT is risk-free, or that the duration-dependent increase is gone. See our full explainer: FDA removes HRT warning: what it means and HRT black box warning history.

If breast cancer runs in your family

Family history of breast cancer is not an automatic “no”to HRT — but it raises the bar for a careful conversation. Here’s the distinction that matters most: having a first-degree relative (mother, sister) who was diagnosed with breast cancer in her 70s is a different risk picture than a mother and aunt both diagnosed under 50, especially if a BRCA1 or BRCA2 gene variant is in the family.

What “family history” calls for is an individual risk assessment, not a blanket policy. Factors that matter:

• Which relative, and how closely related?
• How old were they at diagnosis?
• Is there a known BRCA or other pathogenic variant in the family?
• What type of breast cancer was it?
• What kind of HRT are you considering, and for how long?

The right move before starting anything is to get your baseline risk assessed with a clinician who knows your family history in detail. The NCI’s Breast Cancer Risk Assessment Tool (Tyrer-Cuzick) can help frame the conversation. Family history alone is not the same as a personal diagnosis, and many women with family history use HRT safely — but they deserve the fuller conversation, not a quick intake form.

If you’ve had breast cancer yourself

This is the one firm line in this guide: full-body HRT is generally avoided after breast cancer, especially hormone-receptor-positive cancer, because of recurrence concerns. The evidence isn’t entirely unanimous — a small number of randomized studies have explored HRT after early-stage breast cancer, with mixed results — but the dominant clinical position, supported by ACOG, The Menopause Society, and most oncology guidelines, is to avoid it until the full risk picture is discussed with your cancer care team.

Low-dose vaginal estrogen is a different and sometimes more permissible question, especially for women with severe genitourinary symptoms who have exhausted non-hormonal options. This is a nuanced oncology discussion — particularly for women on aromatase inhibitors, where even vaginal estrogen’s low systemic absorption matters. But it’s a conversation worth having with your oncologist.

For non-hormonal symptom management options, see our guide to non-hormonal menopause options.

When a clinician review makes sense — and when telehealth may fit

If you’re in the green lane below — no personal breast cancer history, no major red flags, considering symptom relief near menopause — the conversation is a routine one, and a menopause-trained clinician is the right next step. That can be your OB-GYN, a menopause specialist, or a telehealth provider with genuine specialist depth.

If you’re in the yellow lane, you’re not blocked. You need a more careful conversation, ideally with someone who regularly sees complex histories. Telehealth can work here too — if the platform has the right clinical depth. If you’re in the red lane (personal breast cancer history, active breast change, or current cancer treatment), the right first step is an oncology or specialist evaluation, not an online signup form.

Disclosure:The HRT Index is the independent menopause-HRT decision resource for women telehealth providers, and we may earn a commission if you use some of the links below. That never changes what we tell you. For this question — which involves real cancer risk history — we deliberately point you toward careful review first, not the highest-paying signup.

For a broader comparison of menopause telehealth platforms, see our best telehealth for HRT guide.

What to ask your doctor about HRT and breast cancer risk

Most 15-minute appointments run out of time before the important questions get asked. Here is a short list worth bringing in writing:

1. What type of HRT are you recommending, and why this one for my situation? (estrogen-only vs. combined; progestogen type if combined)
2. Do I still have my uterus?(If your records aren’t clear, confirm before starting — it’s the most decisive variable.)
3. What’s my personal baseline breast cancer risk, taking into account my family history, breast density, and age?
4. How long do you expect me to be on this, and how do we reassess?
5. Should my mammogram screening schedule changewhile I’m on combined HRT? (It can increase breast density, which affects mammogram reads.)
6. Is micronized progesterone an option instead of a synthetic progestin if I need a combined approach?
7. What are the non-hormonal alternatives if the breast cancer risk picture makes HRT a poor fit for me?
8. How will we monitor for breast changeswhile I’m on this therapy?

Where do you fit? A three-path summary

If you’re in the green lane, the data should reassure you: a small, mostly-but-not-fully-reversible increase in breast cancer risk with combined HRT — and little to none with estrogen-only or vaginal estrogen — weighed against real relief and benefits like better sleep, fewer hot flashes, and bone protection. It’s also worth knowing that hormone therapy is not linked to a higher risk of dying from all causes (NCI). That’s a decision you’re allowed to make.

If you’re in the yellow lane, you’re not blocked — you just deserve a closer look first. And if you’re in the red lane, the most caring thing we can do is point you to the right specialist instead of an order form.

Wherever you land, you now know more about HRT and breast cancer risk than most people who walk into the appointment — including, sometimes, more than the headline that scared you here.

How we researched this guide

We built this page from primary and high-authority medical sources, then assembled an original risk-by-type comparison around the questions readers actually ask. We kept medical facts and commercial information strictly separate, and we verified the 2026 FDA changes against the FDA’s own published materials.

For the medical and regulatory claims, we relied on, in order of weight: the FDA’s labeling and safety communications; the U.S. National Cancer Institute; the published Women’s Health Initiative trial results; large pooled analyses including the Collaborative Group on Hormonal Factors in Breast Cancer (The Lancet) and the Million Women Study; and guidance from menopause and cancer organizations including The Menopause Society and ACOG. We use the term “HRT” (hormone replacement therapy) throughout because that’s what most people search; clinicians increasingly call it “MHT” (menopausal hormone therapy), and the two mean the same thing here.

We are not your doctors, and this is not medical advice. Nothing here replaces a personal assessment with a clinician who knows your history.

Frequently asked questions